Supplemental Table I. Sex-Specific Multivariable-Adjusted* Regressions for ALT<40 U/L with Cardiometabolic Risk Factors

	Women	(N=1243)	Men	(N=1056)
	MV adjusted beta coefficient or OR (95% CI)	**p-value**	**MV adjusted beta coefficient or OR (95% CI)**	**p-value**
Continuous Variables				
Systolic Blood Pressure				
Base Model*	1.08 (-0.02, 2.17)	0.06	2.39 (1.10, 3.69)	0.0003
+VAT	0.39 (-0.69, 1.47)	0.48	1.73 (0.42, 3.03)	0.01
+HOMA-IR	0.75 (-0.36, 1.86)	0.19	2.25 (0.96, 3.54)	0.0006
+BMI	0.29 (-0.80, 1.38)	0.60	1.76 (0.46, 3.06)	0.008
Diastolic Blood Pressure				
Base Model*	0.95 (0.32, 1.57)	0.003	2.38 (1.56, 3.19)	<0.0001
+VAT	0.61 (-0.01, 1.23)	0.06	1.89 (1.08, 2.71)	<0.0001
+HOMA-IR	0.81 (0.18, 1.45)	0.01	2.31 (1.50, 3.13)	<0.0001
+BMI	0.55 (-0.07, 1.18)	0.08	1.89 (1.08, 2.70)	<0.0001
Fasting Plasma Glucose				
Base Model*	1.76 (0.82, 2.70)	0.0002	1.72 (0.28, 3.16)	0.02
+VAT	0.79 (-0.10, 1.68)	0.08	0.93 (-0.52, 2.38)	0.21
+BMI	0.80 (-0.11, 1.71)	0.09	0.78 (-0.66, 2.22)	0.29
Log Triglycerides				
Base Model*	0.06 (0.03, 0.10)	0.0002	0.10 (0.05, 0.15)	0.0003
+VAT	0.02 (-0.01, 0.05)	0.12	0.05 (<0.01, 0.10)	0.08
+HOMA-IR	0.03 (<0.01, 0.07)	0.05	0.08 (0.03, 0.13)	0.003
+BMI	0.03 (-0.01, 0.06)	0.10	0.06 (0.01, 0.11)	0.02
HDL Cholesterol				
Base Model*	-1.22 (-2.31, -0.14)	0.03	-0.89 (-1.98, 0.20)	0.11
+VAT	-0.15 (-1.18, 0.88)	0.77	0.29 (-0.76, 1.34)	0.59
+HOMA-IR	-0.34 (-1.40, 0.73)	0.54	-0.52 (-1.58, 0.53)	0.33
+BMI	-0.15 (-1.20, 0.91)	0.79	-0.01 (-1.08, 1.06)	0.99
HOMA-IR				
Base Model*	0.42 (0.30, 0.54)	<0.0001	0.28 (0.08, 0.48)	0.007
+VAT	0.25 (0.14, 0.35)	<0.0001	0.04 (-0.16, 0.23)	0.70
+BMI	0.24 (0.13, 0.35)	<0.0001	0.01 (-0.18, 0.19)	0.94
Dichotomous Variables				

	Effect size (95% CI)	p-value	Effect size (95% CI)	p-value
Hypertension				
Base Model*	1.41 (1.18, 1.68)	0.0001	1.26 (1.00, 1.58)	0.047
+VAT	1.25 (1.04, 1.50)	0.02	1.10 (0.87, 1.39)	0.44
+HOMA-IR	1.20 (0.99, 1.45)	0.06	1.22 (0.96, 1.53)	0.10
+BMI	1.23 (1.02, 1.48)	0.03	1.11 (0.88, 1.41)	0.37
IFG				
Base Model*	1.44 (1.19, 1.74)	0.0001	1.62 (1.31, 2.00)	<0.0001
+VAT	1.27 (1.04, 1.55)	0.02	1.46 (1.18, 1.81)	0.0006
+BMI	1.26 (1.03, 1.53)	0.02	1.50 (1.21, 1.86)	0.0002
Diabetes				
Base Model*	1.57 (1.12, 2.21)	0.01	1.12 (0.75, 1.67)	0.58
+VAT	1.37 (0.96, 1.97)	0.08	1.00 (0.66, 1.51)	1.00
+BMI	1.29 (0.90, 1.86)	0.17	0.98 (0.65, 1.48)	0.93
Metabolic Syndrome				
Base Model*	1.78 (1.49, 2.12)	<0.0001	1.65 (1.32, 2.06)	<0.0001
+VAT	1.50 (1.22, 1.84)	<0.0001	1.26 (0.99, 1.61)	0.06
+HOMA-IR	1.36 (1.11, 1.66)	0.003	1.42 (1.12, 1.81)	0.004
+BMI	1.47 (1.21, 1.80)	0.0001	1.35 (1.05, 1.72)	0.02
Insulin resistance				
Base Model*	1.78 (1.50, 2.11)	<0.0001	1.81 (1.42, 2.31)	<0.0001
+VAT	1.52 (1.25, 1.85)	<0.0001	1.42 (1.09, 1.85)	0.01
+BMI	1.48 (1.21, 1.79)	0.0002	1.49 (1.14, 1.96)	0.004

Data presented include effect size (SE) expressed per 1 SD increase in log ALT for continuous data, and the odds of the condition per 1 SD increase in log ALT with 95% confidence intervals for dichotomous data.

*Adjusted for age, current smoking, high alcohol intake, physical activity, and menopausal status (women only), hormone replacement therapy (women only); for blood pressure, FPG, HDL cholesterol, and log triglycerides, an additional covariate of treatment for HTN, diabetes, or lipid disorders, respectively, was included.

Abbreviations: VAT, visceral adipose tissue; HOMA-IR, homeostasis model of insulin resistance; BMI, body mass index; HDL, high-density lipoprotein; IFG, impaired fasting glucose.